Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selective estrogen receptor modulators: tissue selectivity and differential uterine effects.

S L Silfen1, A V Ciaccia, H U Bryant

  • 1Eli Lilly and Company, Lilly Corporate Center, DC 2244, Indianapolis, IN, USA.

Climacteric : the Journal of the International Menopause Society
|March 26, 2002
PubMed
Summary

Selective estrogen receptor modulators (SERMs) offer tissue-specific effects, but their impact on the uterus varies. Raloxifene shows a favorable uterine safety profile compared to other SERMs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The selective oestrogen receptor modulator, LY362321, is not neuroprotective in a rat model of transient focal ischaemia.

Journal of neuroendocrinology·2008
Same author

Inhibition of glycinamide ribonucleotide formyltransferase results in selective inhibition of macrophage cytokine secretion in vitro and in vivo efficacy in rat adjuvant arthritis.

Clinical and experimental rheumatology·2005
Same author

Differential effects of estrogen and raloxifene on messenger RNA and matrix metalloproteinase 2 activity in the rat uterus.

Biology of reproduction·2004
Same author

The nongenotropic synthetic ligand 4-estren-3alpha17beta-diol is a high-affinity genotropic androgen receptor agonist.

Molecular pharmacology·2004
Same author

Central and peripheral temperature changes in sheep following ovariectomy.

Maturitas·2003
Same author

Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.

Cancer research·2001

Area of Science:

  • Pharmacology
  • Endocrinology
  • Gynecology

Background:

  • Selective estrogen receptor modulators (SERMs) are designed to mimic estrogen's benefits in some tissues while blocking its effects in others.
  • Estrogen therapy is linked to adverse endometrial stimulation, including hyperplasia and cancer.
  • The endometrial response to SERMs is compound-dependent, necessitating differentiation of their effects.

Purpose of the Study:

  • To review and differentiate the endometrial effects of various SERM compounds.
  • To compare molecular mechanisms, preclinical data, and clinical findings related to SERM-induced endometrial changes.

Main Methods:

  • Review of molecular mechanisms of SERM binding to estrogen receptors.
  • Analysis of preclinical uterine effects in tissue culture and animal models.

Related Experiment Videos

  • Evaluation of endometrial findings from clinical studies and experience.

    • Main Results:

    • SERM-induced endometrial stimulation varies significantly among different compounds.
    • Raloxifene demonstrates a distinct and favorable safety profile regarding endometrial effects.
    • Understanding these differences is crucial for SERM development and patient safety.

    Conclusions:

    • SERMs offer a promising therapeutic avenue, but careful evaluation of their endometrial impact is essential.
    • Raloxifene stands out for its minimal endometrial stimulation.
    • Future SERM research should prioritize compounds with improved uterine safety profiles.